GET A QUOTE

Cancer Antigen 19-9 (CA19-9) ELISA Kit

  • Created on the 11 May, 2017.

BACKGROUND

Cancer antigen 19-9 can also be known as tumor sialylated Lewis A antigen, carbohydrate antigen 19-9 or CA19-9, it is a tumor marker or a tumor-associated antigen which is the predominant marker used in pancreatic cancer management. CA19-9 was first discovered in the serum of colon and pancreatic cancer patients and elevated levels are often found in the serum samples of patients having cancer of the pancreato-biliary system (this includes pancreas, biliary tract and gallbladder). In addition, elevated levels of CA19-9 are also identified in a number of other malignancies (for example lung and a number of other gastrointestinal cancers such as esophageal, colorectal and hepatocellular carcinoma). Apart from cancer, CA19-9 levels are elevated in cirrhosis, pancreatitis and diseases of the bile ducts. It is important to take in to account that patients that are genotypically negative for the Lewis blood group antigen, will not have the ability to produce the CA 19-9 antigen even when there is malignant tissue present.

INTENDED USE

Human CA 19-9 ELISA kit can be used for analysing in vitro quantitative concentrations of cancer antigen 19-9 (carbohydrate antigen 19-9, sialylated Lewis A antigen) in human serum and plasma (EDTA and heparin). This assay has a minimum sensitivity limit of 0.2 U/ml.

SENSITIVITY

The minimum detection sensitivity level of human CA-19-9 (sialylated Lewis A antigen) using this human cancer antigen 19-9 ELISA kit was 0.2 U/ml. The dynamic assay range for this kit is 15.0 – 240.0 U/ml.

REFERENCES

  1. CA 19-9: Biochemical and Clinical Aspects. Adv Exp Med Biol. (2015) 867: 247-60. Review. Scarà S., et al.
  2. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. (2007) 33 (3): 266-70. Review. Goonetilleke K.S. and Siriwardena A.K.
  3. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J. (2012) 18 (6): 530-8. Review. Fong Z.V. and Winter J.M.
  4. Serum tumor markers in bile duct cancer–a review. Biomarkers. (2014) 19 (6): 437-43. Review. Grunnet M. and Mau-Sørensen M.
  5. CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem. (1998) 35 (Pt 3): 364-70. Review. Duffy M.J.

ADDITIONAL INFORMATION

  • Full Name: Cancer Antigen 19-9 (CA19-9) ELISA Kit
  • Reactivity: Human
  • Sample Type: Plasma, Serum
  • Sensitivity: 0.2 U/ml

OTHER RELATED ELISA KITS

TESTIMONIALS arrow icon

Your secretory IgA ELISA kit gave good results and I was also really impressed with how quickly we received it.

L. Johnston
PhD Student / University of Glasgow

It is refreshing to know that you have a technical team that is very knowledgeable. I have already recommended your company to other researchers in our department.

Dr. P. Anderson
Lecturer / University College London (UCL)

I am a first time user and found that your instruction manual was very easy to follow. The insulin ELISA kit performed well and I was happy with the results that were generated.

J. Thomas
Senior Technician / Addenbrooke’s Hospital

I carried out a pilot study comparing the performance of many ELISA kits from different suppliers and found your kits to be one of the better performers. We observed good linearity and tight replicates.

Dr. C. Davies
Lead Scientists / AstraZeneca

You are my first point of contact when I am looking to purchase ELISA kits. You have such an easy and simple system, yet it is very effective.

A. Shaw
Purchasing / University of Oxford